Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Single-arm, Non-randomized Clinical Study to Evaluate the Efficacy and Safety of Hyperbaric Oxygen Therapy Plus Camrelizumab as a Second-line Treatment in Advanced/Metastatic Hepatocellular Carcinoma

NCT05031949 is registered in ClinicalTrials.gov with Zhang Bi Xiang, MD as lead sponsor.

NCT NCT05031949
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05031949 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Single-arm, Non-randomized Clinical Study to Evaluate the Efficacy and Safety of Hyperbaric Oxygen Therapy Plus Camrelizumab as a Second-line Treatment in Advanced/Metastatic Hepatocellular Carcinoma
Lead sponsor
Zhang Bi Xiang, MD
Phase
Phase 1
Overall status
Unknown status
Start date
October 30, 2021
Completion date
June 30, 2025
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

combinational immunotherapy, hepatocellular carcinoma non-resectable, hyperbaric oxygen therapy